A phase II trial of second-line erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC).
Puneeth Iyengar
No relevant relationships to disclose
Brian D. Kavanagh
No relevant relationships to disclose
Irma Smith
No relevant relationships to disclose
Chul Ahn
No relevant relationships to disclose
David E. Gerber
No relevant relationships to disclose
Johnathan Dowell
No relevant relationships to disclose
Randall S. Hughes
No relevant relationships to disclose
Ramzi Abdulrahman
No relevant relationships to disclose
D. Ross Camidge
No relevant relationships to disclose
Laurie E. Gaspar
No relevant relationships to disclose
Robert Charles Doebele
No relevant relationships to disclose
Paul A. Bunn
No relevant relationships to disclose
Hak Choy
No relevant relationships to disclose
Robert D. Timmerman
No relevant relationships to disclose